Neurocrine biosciences announces initiation of phase 3 registrational program for osavampator as an adjunctive therapy for the treatment of major depressive disorder in adults

San diego , jan. 28, 2025 /prnewswire/ -- neurocrine biosciences, inc.  (nasdaq: nbix) today announced the initiation of a phase 3 registrational study to evaluate the efficacy, safety and tolerability of osavampator (formerly nbi-1065845), an investigational drug under development as an adjunctive treatment to antidepressants for major depressive disorder (mdd). positive topline data for the phase 2 savitri™ study of osavampator in adult subjects with mdd were announced in april 2024.
NBIX Ratings Summary
NBIX Quant Ranking